Nuclear Receptors and Stress Response Pathways Associated with the Development of Oral Mucositis Induced by Antineoplastic Agents.

antineoplastic agent molecular initiating event oral mucositis

Journal

Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453

Informations de publication

Date de publication:
20 Aug 2024
Historique:
received: 08 07 2024
revised: 16 08 2024
accepted: 19 08 2024
medline: 31 8 2024
pubmed: 31 8 2024
entrez: 29 8 2024
Statut: epublish

Résumé

Oral mucositis (OM) is one of the common adverse events associated with cancer treatment that decreases the quality of life and affects treatment outcomes. However, the medications used to manage OM are generally only palliative, and our knowledge of the syndrome is limited. The etiology of the syndrome is thought to be complex and multifactorial. We investigated the trends and characteristics of OM and estimated molecular initiating events (MIEs) associated with the development of the syndrome using the FDA Adverse Event Reporting System. The study of trends and characteristics suggested that OM is significantly more likely to occur in females and nonelderly patients and is likely to be induced by protein kinase inhibitors such as afatinib and everolimus. Next, we used Toxicity Predictor, an in-house quantitative structure-activity relationship system, to estimate OM-associated MIEs. The results revealed that the agonist activity of the human pregnane X receptor, thyroid-stimulating hormone-releasing hormone receptor, and androgen receptor may be associated with OM development. Our study findings are expected to help avoid the risk of OM induction during the drug discovery process and clinical use of antineoplastic agents.

Identifiants

pubmed: 39204191
pii: ph17081086
doi: 10.3390/ph17081086
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : JSPS KAKENHI
ID : 22K06707

Auteurs

Moena Kagaya (M)

Department of Medical Molecular Informatics, Meiji Pharmaceutical University, Tokyo 204-8588, Japan.

Yoshihiro Uesawa (Y)

Department of Medical Molecular Informatics, Meiji Pharmaceutical University, Tokyo 204-8588, Japan.

Classifications MeSH